within Pharmacolibrary.Drugs.ATC.G;

model G01AF19
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.01,
    Cl             = 0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Sertaconazole is an imidazole antifungal agent primarily used for the topical treatment of dermatological fungal infections, such as dermatophytosis and candidiasis. It is approved for topical use in several countries and exerts its effect by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes.</p><h4>Pharmacokinetics</h4><p>No published pharmacokinetic data with model parameters for sertaconazole were found. The available data suggest minimal systemic absorption via topical administration in healthy adults.</p><h4>References</h4><ol><li><p>Carrillo-Muñoz, AJ, et al., &amp; Quindós, G (2013). Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. <i>Expert review of anti-infective therapy</i> 11(4) 347–358. DOI:<a href=&quot;https://doi.org/10.1586/eri.13.17&quot;>10.1586/eri.13.17</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23566144/&quot;>https://pubmed.ncbi.nlm.nih.gov/23566144</a></p></li><li><p>Susilo, R, et al., &amp; Menke, A (2005). Rate and extent of percutaneous absorption of sertaconazole nitrate after topical administration. <i>Arzneimittel-Forschung</i> 55(6) 338–342. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1296869&quot;>10.1055/s-0031-1296869</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16032974/&quot;>https://pubmed.ncbi.nlm.nih.gov/16032974</a></p></li><li><p>Sahoo, S, et al., &amp; Sahoo, SK (2016). Effect of microemulsion in topical sertaconazole hydrogel: in vitro and in vivo study. <i>Drug delivery</i> 23(1) 338–345. DOI:<a href=&quot;https://doi.org/10.3109/10717544.2014.914601&quot;>10.3109/10717544.2014.914601</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24845480/&quot;>https://pubmed.ncbi.nlm.nih.gov/24845480</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G01AF19;
